How much does a box of Quizartinib cost? Market reference

Quizartinib(Quizartinib) is a targeted drug that has attracted much attention in the field of international hematology in recent years. It mainly targets patients with acute myeloid leukemia (AML) who carry specific gene mutations. As a selective FLT3 inhibitor, quizartinib blocks tumor cell growth signals and inhibits abnormal proliferation pathways, thus showing high application value in refractory and relapsed patients. For patients, the benefits of quizartinib are not only to inhibit disease progression, but also to be reflected in the flexibility of its treatment plan and sustainable management, making it an innovative targeted drug that has been included in treatment guidelines in many countries around the world.

Since the original drug of Quizartinib has not yet completed marketing approval in China, there is currently no official pricing and medical insurance information in the country. According to market conditions, the more common European original drugs currently include 17.7 mg 28 tablets and 26.5 mg 56 tablets. The overall price is roughly in the range of RMB 80,000 to more than RMB 100,000. The actual cost will still be affected by factors such as exchange rate fluctuations, supply batches, and agency channels. Therefore, when patients understand the price of Quizartinib, they usually need to pay attention to real-time exchange rates and quotations from formal cross-border channels to avoid risks arising from irregular drug purchase routes.

It is worth noting that some overseas regions have launched generic versions of Quizartinib, especially the 14-piece generic version of Lucius Pharmaceuticals in Laos. The price is only about 1,000 yuan, which is significantly lower than the cost of the original drug. The launch of generic drugs brings more choices to price-sensitive patient groups. Their ingredients are basically the same as the original drugs, and the production standards are subject to quality review by local regulatory agencies. However, it needs to be emphasized that the long-term efficacy, drug consistency, quality of raw materials, etc. of generic drugs still need to be evaluated by physicians before deciding whether to use them.

Reference materials:https://go.drugbank.com/drugs/DB12874